Basel-based startup KetoSwiss has completed a 2nd closing of our pre-series A financing round, bringing the total capital raised to $4.8 million. The startup is well-positioned to advance its developments while pushing its flagship product MigraKet in the market.
Migraine affects around one billion people worldwide; however, there are currently no medical solutions for this common neurological disorder targeting the root cause. KetoSwiss has developed a novel medical food for the dietary-preventive therapy of migraine and related diseases that are characterized by metabolic dysfunction. Through this approach, the startup is on a mission to become the leading market player in the medical food area, while continuing R&D into potential drug avenues.
Its first flagship MigraKet is a medical food for migraine and a product of the Brain Ritual brand. It pairs the brain’s most ancient fuel with crucial micronutrients necessary for the brain’s energy metabolism. With this, KetoSwiss offers a holistic, clinically tested, and patent-protected solution.
Last year in October, KetoSwiss secured investment from various investors to advance its product development. This year, the company has obtained an additional $ 0.8 million, bringing the total capital raised in the pre-series A round to $4.8m.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines